Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics, Inc. develops oral small-molecule therapies for neuroscience, inflammation and immunology indications. Company news centers on its clinical pipeline, including PIPE-791, an LPA1 receptor antagonist in development for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis and major depressive disorder.
Recurring updates include clinical trial data, PIPE-791 program progress, financial results, capital allocation commentary, investor conference participation and equity compensation actions under Nasdaq inducement-grant rules. Coverage also reflects the company’s Class A common stock structure and its status as a clinical-stage biopharmaceutical issuer.
Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharma company focusing on neuroscience, inflammation, and immunology therapies, announced the appointment of Troy Ignelzi as an independent board member and Chair of the Audit Committee.
Mr. Ignelzi, currently CFO at Rapport Therapeutics, has nearly two decades of financial leadership. His previous roles include CFO positions at Karuna Therapeutics, Juventas Therapeutics, and scPharmaceuticals. He also has experience with Eli Lilly and other biotech companies.
Mr. Ignelzi's expertise in public markets and financing precision neuroscience companies is expected to aid Contineum's development of therapies targeting fibrotic and neurological disorders.
Contineum Therapeutics (Nasdaq: CTNM) reported financial results for Q1 2024 and announced significant corporate progress. The company successfully completed its IPO, netting $108 million, extending its cash runway to 2027. Key developments include the initiation of a Phase 2 trial for PIPE-307 in RRMS and a planned Phase 1b trial for PIPE-791. Contineum also nominated a third development candidate, CTX-343, and presented positive data on PIPE-791 at the Myelin Gordon Conference. Financially, the company reported $117.9 million in cash and securities, with increased R&D expenses of $7.8 million and G&A expenses of $2.2 million.
Summary not available.